Association between serum netrin-1 levels and early neurological deterioration after acute ischemic stroke

Zhuo Chen¹, Tianli Cao¹, Xingju Zhong¹, Yong Wu¹, Wei Fu¹, Chaoli Fan¹, Yu Jiang¹, Qi Zhou¹, Jie Peng¹, Jieyu Liao¹, Zhike You¹, Xin Yi¹ and Jingyu Tan²*

¹Department of Neurology, Mianzhu People’s Hospital, Mianzhu, China. ²Department of Endocrinology, Mianzhu People’s Hospital, Mianzhu, China

Background and purposes: Experimental studies demonstrated that netrin-1 (NT-1) has anti-inflammatory, tissue regeneration, and immune modulation properties. We aimed to discern the utility of NT-1 as a biomarker for assessing the risk of early neurological deterioration (END) after ischemic stroke.

Methods: This was a prospective study enrolling ischemic stroke patients with symptoms onset <24 h. Serum NT-1 concentrations were measured at admission. The National Institutes of Health Stroke Scale increased by >2 points and >4 points during the first 72 h after admission and was defined as END2 and END4, respectively.

Results: The study included 268 patients (146 men and 122 women) with a mean age of 63.0 ± 9.6 years. The median NT-1 concentrations were 466.4 pg/ml (interquartile range, 341.4–589.2 pg/ml). During the initial 72 h after admission, END2 was found in 83 (31.0%) patients, and END4 was observed in 48 (17.9%) subjects. After adjusted for potential confounders, multivariate analysis indicated that decreased NT-1 levels is an independent predictor for END2 (odds ratio (OR) 0.62, 95% confidence interval (CI) 0.46–0.84, p < 0.001) and END4 (OR 0.53, 95% CI 0.36–0.76, p < 0.001). Similar results were found when the NT-1 levels were analyzed as a categorical variable. Furthermore, restricted cubic spline analysis showed a linear association between NT-1 concentrations and the risk of END (END2, p = 0.006 for linearity; END4, p < 0.001 for linearity).

Conclusions: Our results suggest that decreased NT-1 levels were significantly associated with a higher risk of END after ischemic stroke.

Keywords: acute ischemic stroke, early neurological deterioration, biomarker, netrin-1, restricted cubic spline
Introduction

Ischemic stroke is a leading cause of death and adult disability globally, exerting a heavy economic burden (1). According to the literature, approximately one-third of patients with acute ischemic stroke (AIS) would experience early neurological deterioration (END) during hospitalization despite standard treatment (2–4). END is frequently associated with an increased risk of functional disability and mortality (5–7). Therefore, to effectively improve the ischemic stroke outcome, it is essential to accurately identify the risk factor of END after AIS.

Netrin-1 (NT-1) is a bifunctional molecule, identified as a neuronal guidance cue, and directs axons to its targets during the development of the nervous system (8, 9). NT-1 receptors include the deleted in colorectal cancer and uncoordinated-5 families, which belonged to the transmembrane immunoglobulin superfamily (10). It has been reported that NT-1 is involved in several physiological and pathological processes such as dysfunction of the blood–brain barrier, apoptosis, neuroinflammation, and neurogenesis in animal models of cerebral ischemia (11–13). In addition, the overexpression of NT-1 by adeno-associated viral could increase peri-infarct blood vessel density and improve motor function recovery after experimental stroke (14), indicating that NT-1 might play an important role in mediating cerebral injury after ischemic stroke. Recently, several clinical studies have evaluated the prognostic value of NT-1 in ischemic stroke. According to the data from the China Antihypertensive Trial in AIS, decreased baseline NT-1 was significantly correlated to a higher risk of the 90-day composite outcome of death or major disability, and there was a negative linear dose–response relationship between them (15). We also confirmed the important role of NT-1 in predicting depression at 3 months after ischemic stroke (16). However, to date, the association between NT-1 levels and AIS complications, such as END, has not been well-clarified. Therefore, we aimed to prospectively assess the relationship between NT-1 levels and the risk of END in patients with AIS.

Materials and methods

Study population

From July to December 2021, consecutive patients who were admitted to the Mianzhu People’s Hospital due to first-ever AIS within 24 h of symptom onset were prospectively recruited. AIS was diagnosed according to the World Health Organization criteria (17) and was sequentially confirmed by brain computed tomography or magnetic resonance confirmation. We then excluded participants based on the following exclusion criteria: (1) age <18 years; (2) received the intravenous thrombolysis and/or endovascular treatment after admission; (3) discharged early within 3 days after admission. This study was approved by the Ethics Review Board of Mianzhu People’s Hospital. Written informed consent was obtained from each participant or proxy respondent.

Clinical data collection

We acquired clinical data from each patient, such as demographic characteristics, body mass index (BMI), vascular risk factors, medication history, stroke severity, stroke etiology, and initial hematological findings such as uric acid, hypersensitive C-reactive protein (Hs-CRP), and baseline glucose levels. The severity of the index stroke was evaluated by the National Institutes of the Health Stroke Scale (NIHSS) (18). Ischemic stroke was further classified with reference to TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria (19).

Assessment of END

The stroke severity was evaluated by an experienced neurologist using NIHSS at admission and continued 1–3 times a day for 72 h. In our study, we used two previously recommended END definitions to diagnose the presence of END. The first definition (END2) is that the total NIHSS score increased at least two points compared with the baseline NIHSS score (2, 20). The second definition (END4) is that the total NIHSS score increased at least four points compared with the baseline NIHSS score (20, 21).

Determination of NT-1 levels

Blood was sampled from each subject within 24 h after admission. The specimens were centrifuged at 1,500 g for 10 min and the isolated serum was frozen at −80°C for later analysis. NT-1 levels were measured using commercially available enzyme-linked immunosorbent assay kits according to manufacturers’ instructions, by laboratory technicians who were blinded to clinical data.

Statistical analyses

Categorical variables are expressed as the number of patients (%) and were compared using the chi-square test. Continuous variables are expressed as mean (standard deviation, SD) or median (interquartile range, IQR) for the continuous variables. Student’s t-test, the Mann–Whitney U test, the one-way analysis of variance, and the Kruskal–Wallis H test were applied to compare continuous variables between groups as appropriate. A binary logistic regression analysis was conducted to evaluate the

Frontiers in Neurology
TABLE 1 Baseline data according to the quartile of netrin-1 levels.

| Variables                  | First quartile n = 67 | Second quartile n = 67 | Third quartile n = 67 | Fourth quartile n = 67 | P-value |
|----------------------------|-----------------------|------------------------|-----------------------|------------------------|---------|
| Demographic characteristics |                       |                        |                       |                        |         |
| Age, year                  | 66.1 ± 8.8            | 62.0 ± 9.7             | 61.5 ± 8.9            | 62.5 ± 10.6            | 0.023   |
| Male, n (%)                | 38 (56.7)             | 35 (52.2)              | 38 (56.7)             | 35 (52.2)              | 0.910   |
| BMI, kg/m²                 | 24.6 ± 2.7            | 24.3 ± 2.3             | 25.0 ± 2.8            | 24.5 ± 2.9             | 0.510   |
| Vascular risk factors, n (%) |                      |                        |                       |                        |         |
| Hypertension               | 48 (71.6)             | 46 (68.7)              | 46 (68.7)             | 50 (74.6)              | 0.850   |
| Diabetes                   | 30 (44.8)             | 18 (26.9)              | 19 (28.4)             | 10 (14.9)              | 0.002   |
| Hyperlipidemia             | 7 (10.4)              | 10 (14.9)              | 14 (20.9)             | 12 (17.9)              | 0.397   |
| Coronary heart disease     | 8 (11.9)              | 4 (6.0)                | 6 (9.0)               | 5 (7.5)                | 0.645   |
| Current smoking            | 29 (43.3)             | 29 (43.3)              | 26 (38.8)             | 21 (31.3)              | 0.444   |
| Current alcohol intake     | 18 (26.9)             | 18 (26.9)              | 19 (28.4)             | 14 (20.9)              | 0.765   |
| Clinical parameters        |                       |                        |                       |                        |         |
| Systolic blood pressure, mmHg | 136.9 ± 16.2         | 138.4 ± 17.9           | 137.9 ± 15.6          | 132.9 ± 14.7           | 0.189   |
| Diastolic blood pressure, mmHg | 82.0 ± 10.7        | 80.7 ± 10.3            | 81.7 ± 9.3            | 79.0 ± 8.5             | 0.287   |
| NIHSS score at admission, score | 8.0 (5.0, 10.0)   | 7.0 (4.0, 10.0)        | 6.0 (4.0, 9.0)        | 6.0 (4.0, 9.0)         | 0.058   |
| Previous statin therapy, n (%) | 12 (17.9)           | 17 (25.4)              | 23 (34.3)             | 19 (28.4)              | 0.186   |
| Previous antiplatelet therapy, n (%) | 24 (35.8)         | 21 (31.3)              | 25 (37.3)             | 19 (28.4)              | 0.675   |
| END2, n (%)                | 29 (43.3)             | 22 (32.8)              | 21 (31.3)             | 11 (16.4)              | 0.009   |
| END4, n (%)                | 21 (31.3)             | 11 (16.4)              | 9 (13.4)              | 7 (10.4)               | 0.008   |
| Lesion location, n (%)     |                       |                        |                       |                        | 0.196   |
| Frontal                    | 8 (11.9)              | 8 (11.9)               | 13 (19.4)             | 20 (29.9)              |         |
| Parietal                   | 15 (22.4)             | 12 (17.9)              | 7 (10.4)              | 7 (10.4)               |         |
| Basal ganglia              | 20 (29.9)             | 19 (28.4)              | 23 (34.3)             | 21 (31.3)              |         |
| Infarctial territory       | 12 (17.9)             | 10 (14.9)              | 10 (14.9)             | 7 (10.4)               |         |
| Other                      | 12 (17.9)             | 18 (26.9)              | 14 (20.9)             | 12 (17.9)              |         |
| Stroke subtypes, n (%)     |                        |                        |                        |                        | 0.208   |
| Atherosclerosis            | 30 (44.8)             | 33 (49.4)              | 26 (38.8)             | 21 (31.3)              |         |
| Cardiembolism              | 9 (13.4)              | 14 (20.9)              | 17 (25.4)             | 16 (23.9)              |         |
| Small vessel occlusion     | 22 (32.8)             | 17 (25.4)              | 15 (22.4)             | 25 (37.3)              |         |
| Other                      | 6 (9.0)               | 3 (4.5)                | 9 (13.4)              | 5 (7.5)                |         |
| Laboratory data            |                        |                        |                        |                        |         |
| Baseline glucose levels, mmol/L | 6.1 ± 2.7           | 5.2 ± 1.9              | 6.1 ± 1.9             | 5.4 ± 2.3              | 0.046   |
| Hs-CRP, mg/L               | 7.5 (2.2, 12.0)       | 3.5 (1.9, 8.6)         | 5.8 (2.7, 9.9)        | 3.3 (1.6, 5.5)         | 0.002   |
| Uric acid, mmol/L          | 323.7 ± 97.3          | 309.2 ± 99.9           | 315.8 ± 107.7         | 303.4 ± 82.5           | 0.662   |

Hs-CRP, Hyper-sensitive C-reactive protein; NIHSS, National Institutes of Health Stroke Scale; PSD, post-stroke depression.

We evaluated a total of 268 patients with AIS (mean age: 63.0 years; male: 54.5%; median NIHSS score: 6.0). The study association between NT-1 concentrations and the risk of END. A further multivariate model was computed after adjusting for demographic characteristics and variables with p < 0.1 in the univariate analysis. The results are demonstrated as odds ratio (OR) with 95% confidence intervals (CI). We also used the multiple imputations with chain equations to account for missing values.

We further explored the pattern and magnitude of the association of NT-1 levels with END using restricted cubic splines with 3 knots (at 5th, 50th, and 95th percentiles) adjusted for potential covariates (22). All statistical analysis was conducted with SPSS for Windows version 23.0 (SPSS Inc., Chicago, IL, USA) and R statistical software version 4.0.0 (R Foundation, Vienna, Austria). A two-sided p-value of < 0.05 was considered to be statistically significant.

Results

We evaluated a total of 268 patients with AIS (mean age: 63.0 years; male: 54.5%; median NIHSS score: 6.0). The study
TABLE 2 Univariate analysis of the factors with early neurological deterioration.

| Variables                                    | END2                     | P-value     | END4                     | P-value     |
|----------------------------------------------|--------------------------|-------------|--------------------------|-------------|
| Demographic characteristics                 |                          |             |                          |             |
| Age, year                                    | 64.8 ± 8.3               | 0.048       | 64.1 ± 8.3               | 0.387       |
| Male, n (%)                                  | 45 (54.2)                | 0.954       | 25 (52.1)                | 0.713       |
| BMI, kg/m²                                    | 24.3 ± 2.6               | 0.252       | 24.2 ± 2.6               | 0.298       |
| Vascular risk factors, n (%)                 |                          |             |                          |             |
| Hypertension                                 | 68 (81.9)                | 0.008       | 37 (77.1)                | 0.288       |
| Diabetes                                     | 32 (38.6)                | 0.017       | 20 (41.7)                | 0.029       |
| Hyperlipidemia                               | 14 (16.9)                | 0.806       | 7 (14.6)                 | 0.761       |
| Coronary heart disease                       | 7 (8.4)                  | 0.954       | 4 (8.3)                  | 0.946       |
| Current smoking                              | 37 (44.6)                | 0.225       | 18 (37.5)                | 0.793       |
| Current alcohol intake                       | 26 (31.3)                | 0.162       | 11 (22.9)                | 0.621       |
| Clinical parameters                          |                          |             |                          |             |
| Systolic blood pressure, mmHg                | 138.1 ± 16.6             | 0.244       | 138.5 ± 17.0             | 0.346       |
| Diastolic blood pressure, mmHg               | 81.6 ± 9.2               | 0.411       | 81.2 ± 8.2               | 0.829       |
| NIHSS score at admission, score              | 7.0 (5.0, 10.0)          | 0.048       | 7.5 (5.0, 12.0)          | 0.003       |
| Previous statin therapy, n (%)               | 24 (28.9)                | 0.547       | 12 (25.0)                | 0.796       |
| Previous antiplatelet therapy, n (%)         | 31 (37.3)                | 0.335       | 16 (33.3)                | 0.984       |
| Lesion location, n (%)                       | 0.960                    | 0.977       |                          |             |
| Frontal                                      | 14 (16.9)                | 8 (16.7)    | 41 (18.6)                | 0.977       |
| Parietal                                     | 13 (15.7)                | 8 (16.7)    | 33 (15.0)                |             |
| Basal ganglia                                | 25 (30.1)                | 15 (31.3)   | 68 (30.9)                |             |
| Infratentorial                               | 14 (16.9)                | 8 (16.7)    | 31 (14.1)                |             |
| Other                                        | 17 (20.5)                | 9 (18.8)    | 47 (21.4)                |             |
| Stroke subtypes, n (%)                       | 0.414                    | 0.932       |                          |             |
| Atherosclerosis                              | 36 (43.4)                | 20 (41.7)   | 90 (40.9)                |             |
| Cardioembolism                               | 20 (24.1)                | 10 (20.8)   | 46 (20.9)                |             |
| Small vessel occlusion                       | 23 (27.7)                | 15 (31.3)   | 64 (29.1)                |             |
| Other                                        | 4 (4.8)                  | 3 (6.3)     | 20 (9.1)                 |             |
| Laboratory data                              |                          |             |                          |             |
| Baseline glucose levels, mmol/L              | 6.1 ± 2.6                | 0.033       | 6.6 ± 3.0                | < 0.001     |
| Hs-CRP, mg/L                                 | 6.5 (2.6, 9.9)           | 0.009       | 6.9 (2.1, 10.0)          | 0.061       |
| Uric acid, mmol/L                            | 317.4 ± 102.7            | 0.621       | 392.7 ± 117.8            | 0.431       |
| Netrin-1 level, pg/mL                        | 432.5 (290.3, 490.2)     | < 0.001     | 389.8 (276.2, 489.1)     | < 0.001     |
| Netrin-1 quartiles, n (%)                    | 0.009                    | 0.008       |                          |             |

Hs-CRP, Hyper-sensitive C-reactive protein; NIHSS, National Institutes of Health Stroke Scale; PSD, post-stroke depression.

population, 190 patients had hypertension, 77 had diabetes mellitus, 43 had hyperlipidemia, and 22 patients had coronary heart disease. The median levels of NT-1 in this cohort were 466.4 pg/ml, with quartile levels as follows: first quartile (<342.8 pg/ml), second quartile (342.8–466.3 pg/ml), third quartile (466.4–589.0 pg/ml), and fourth quartile (>589.0 pg/ml). The demographic characteristics and clinical and laboratory data are summarized in Table 1. Patients with lower NT-1 levels showed significantly older age (p = 0.023), higher prevalence of diabetes (p = 0.002), END2 (p = 0.009) and END4 (p =
Early neurological deterioration is a common complication of AIS. The major causes of END include hemorrhagic transformation, malignant edema, progressive stroke, and poststroke seizure (3, 23). The incidence of patients with END was vary widely in previous studies, depending on the definition used. In the present study, END was observed in 31.0% of patients, which is defined as a significant neurofunctional decline (increment of NIHSS score by two points) within a 72-h period after admission. This incidence of END was similar to the previous studies (2–4). The important finding of the present study was that decreased NT-1 levels were associated with a higher rate of END, independent of demographic characteristics, baseline NIHSS score, and other potential confounders.

Accumulating evidence indicated that NT-1 could be used to reflect risk and severity in cerebrovascular disease patients (15, 24–27). The previous cross-sectional studies found that NT-1 levels were significantly associated with a higher risk of END after ischemic stroke, and lower NT-1 levels. Furthermore, patients with END2 were older than patients without (p = 0.048). Hypertension was more prevalent in patients with END2 than in patients without (p = 0.008). The baseline NIHSS score (p = 0.048) and the Hs-CRP levels (p = 0.009) were higher in patients with END2 than in patients without END2. After adjustment for age, sex, baseline NIHSS score, and other potential confounders, multivariate analysis showed that patients with the lowest quartile of NT-1 levels were significantly associated with a higher risk of END2 (as compared with higher quartile of NT-1 levels; OR, 3.46; 95% CI, 1.44–8.31; p = 0.005) and END4 (as compared with higher quartile of NT-1 levels; OR, 3.18; 95% CI, 1.16–8.74; p = 0.025). Similar results were found when the NT-1 levels were analyzed as a continuous variable (Table 3).

In addition, restricted cubic spline analysis showed a linear association between NT-1 concentrations and the risk of END (Figure 1A, END2, p = 0.006 for linearity; Figure 1B, END4, p < 0.001 for linearity).

### Discussion

Several pathophysiological mechanisms could explain the observed effect of NT-1 on neurological deterioration after ischemic stroke. First, NT-1 presents bifunctional effects on blood vessels through receptor-dependent pathways. In middle cerebral artery occlusion rats, intracerebroventricularly infusion of NT-1 could ameliorate the blood–brain barrier impairment secondary to ischemic stroke by promoting tight junction function and endothelial survival via activating the PI3K Pathway (13). Second, It is known that NT-1 is a laminin-related protein enriching axonal extension and regulating angiogenesis (8, 9). The growth of new capillary blood vessels increases the...
blood supply in the ischemic penumbra and functions as a scaffold to translate the neurons to the ischemic periphery (28). AAV-mediated netrin-1 overexpression also improves the peri-infarct vascular density, which might reduce the infarct size and improve functional recovery (14). In addition, systemic human NT-1 gene delivery by AAV can reduce leukocyte accumulation, which in turn inhibits neuroinflammation and brain parenchymal injury (29). Taken together, NT-1 might prevent neurological deterioration after ischemic stroke by mediating the permeability of the blood–brain barrier, endothelial function, inflammation, and angiogenesis. Further clinical trials are needed to assess whether patients with ischemic stroke could benefit from the exogenous NT-1 supplement.

Several limitations of this study merit consideration. First, due to the limitation inherent in the cross-sectional study, we could only show association, not causality. Second, NT-1 concentrations were measured only once after admission. NT-1 levels should be measured dynamically for longitudinal analysis, which might provide additional information on the development and its prognostic implications. Third, patients with AIS who received reperfusion therapy were excluded from this study, which might underestimate the actual incidence of END and limit the generalizability of our results. Finally, the previous studies used inconsistent definitions of END, leading to the discrepancy in incidence rates and associated factors. However, the 2 END definitions used in our study have been widely accepted and recommended by researchers.

In conclusion, AIS patients with decreased baseline NT-1 levels were easier to experience END during hospitalization, which may be an important indicator for risk stratification of END after AIS. Future studies are warranted to validate our findings and explore the detailed pathway of NT-1 in mediating the neurological fluctuation after ischemic stroke.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Review Board of Mianzhu People’s Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

JT and ZC designed and conceptualized the study, analyzed the data, interpreted the data, drafted, and revised the manuscript. TC, XZ, YW, WF, CF, YJ, QZ, JP, JL, ZY, and XY...
played a major role in the acquisition. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Collaborators. G.S. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. (2018) 17:849–58. doi: 10.1016/S1474-4422(19)30034-1

2. Sierig J, Martin-Schild S. Early neurological deterioration (END) after stroke: the END depends on the definition. Int J Stroke. (2011) 6:211–2. doi: 10.1111/j.1747-4949.2011.00596.x

3. Thanvi B, Treadwell S, Robinson T. Early neurological deterioration in acute ischemic stroke: predictors, mechanisms and management. Postgrad Med J. (2008) 84:412–7. doi: 10.1136/pgmj.2007.066118

4. Zhang X, Sun Z, Ding C, Tang Y, Jiang X, Xie Y, et al. Metabolic syndrome augments the risk of early neurological deterioration in acute ischemic stroke patients independent of inflammatory mediators: a hospital-based prospective study. Oxid Med Cell Longev. (2016) 2016:8346301. doi: 10.1155/2016/8346301

5. Dávalos A, Toni D, Iwens F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS). J Stroke. (1999) 30:2631–6. doi: 10.1161/01.STR.30.13.2631

6. Yang P, Zhang Y, Zhang L, Zhang Y, Treurniet K, Chen W, et al. Endovascular Thrombectomy with or without Intravenous alteplase in acute stroke. N Engl J Med. (2020) 382:1981–93. doi: 10.1056/NEJMoa2001123

7. Hebbok B, Kurtz P, Vibbert M, Schmidt M, Fernandez L, Lantigua H, et al. Early neurological deterioration after subarachnoid haemorrhage: risk factors and impact on outcome. J Neurol Neurosurg Psychiatry. (2013) 94:266–70. doi: 10.1136/jnnp-2012-302804

8. Rajasekharan S, Kennedy T. The netrin protein family. Genome Biol. (2009) 10:239. doi: 10.1186/gb-2009-10-9-239

9. Moore S, Tessier-Lavigne M, Kennedy T. Netrins and their receptors. Adv Exp Med Biol. (2007) 621:17–31. doi: 10.1007/978-0-387-76175-4_2

10. Huber A, Kolodkin A, Ginty D, Cloutier J. Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. Annu Rev Neurosci. (2003) 26:509–63. doi: 10.1146/annurev.neuro.26.013002.081139

11. Podjuski C, Alvarez J, Bourronniere I, Larouche S, Teroue S, Bin J, et al. Netrin-1 regulates blood-brain barrier function and neuroinflammation. Brain. (2015) 138:1598–612. doi: 10.1093/brain/awv092

12. Liao S, Gong Q, Chen X, Ye L, Ding Q, Zeng L, et al. Netrin-1 rescues neuron loss by attenuating secondary apoptosis in ipsilateral thalamic nucleus pathway. Front Neurosci. (2013) 7:238. doi: 10.3389/fnins.2013.00238

13. Yu J, Li C, Ding Q, Quer J, Liu K, Wang H, et al. Netrin-1 Ameliorates blood-brain barrier impairment secondary to ischemic stroke via the activation of PI3K pathway. Front Neurosci. (2015) 9:370. doi: 10.3389/fnins.2015.00370

14. Sun H, Le T, Chang T, Hahb A, Wu S, Shen F, et al. AAV-mediated netrin-1 overexpression increases peri-infarct blood vessel density and improves motor function recovery after experimental stroke. Neurobiol Dis. (2011) 44:73–83. doi: 10.1016/j.nbd.2011.06.006

15. Guo D, Zha Z, Zhong C, Peng H, Wang A, Xu T, et al. Increased serum netrin-1 is associated with improved prognosis of ischemic stroke. Stroke. (2019) 50:845–52. doi: 10.1161/STROKEAHA.118.024631

16. Chen Z, Cao T, Zhong X, Wu Y, Fu W, Fan C, et al. Decreased serum netrin-1 as a predictor for post-stroke depression in Chinese patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. (2020) 29:105149. doi: 10.1016/j.jstrokecerebrovasdis.2020.105149

17. Stroke—1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders. Stroke. (1989) 20:1407–31. doi: 10.1161/01.STR.20.10.1407

18. Brott T, Adams HJ, Olinger C, Marler J, Barsan W, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. (1989) 20:864–70. doi: 10.1161/01.STR.20.7.864

19. Adams HJ, Bendixen B, Kappelle L, Biller J, Love B, Gordon D. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10,172 in acute stroke treatment. Stroke. (1993) 24:35–41. doi: 10.1161/01.STR.24.1.35

20. Sun W, Liu W, Zhang Z, Xiao L, Duan Z, Liu D, et al. Asymmetrical cortical vessel sign on susceptibility-weighted imaging: a novel imaging marker for early neurological deterioration and unfavorable prognosis. Eur J Neurol. (2014) 21:1411–8. doi: 10.1111/ene.12510

21. Alawneh J, Moustaef R, Baron J. Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke. (2009) 40:e443–50. doi: 10.1161/strokeaha.108.532465

22. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. (1989) 8:551–61. doi: 10.1002/sim.4780080504

23. Kim J, Bae J, Park K, Lee W, Byun J, Ahn S, et al. Incidence and mechanism of early neurological deterioration after endovascular thrombectomy. J Neurol. (2019) 266:609–15. doi: 10.1007/s00415-018-09173-0

24. Chen J, Yuan D, Yang S, Gu C, Zhou H, Shao G. Serum netrin-1 serves as a prognostic biomarker of aneurysmal subarachnoid hemorrhage. Clin Chim Acta. (2019) 495:294–300. doi: 10.1016/j.cca.2019.04.080

25. Lou X, Cai Y, Yang X, Zheng H, Yu Y, Wang C, et al. Serum netrin-1 concentrations are associated with clinical outcome in acute intracerebral hemorrhage. Clin Chim Acta. (2020) 508:154–60. doi: 10.1016/j.cca.2020.10.032

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.